Purpose: Thirty percent of patients with postherpetic neuralgia (PHN) receiving conservative treatment report unsatisfactory pain relief. Epidural steroid injections (ESIs) are commonly used as a therapeutic intervention in these patients. In this study, we aimed to determine if there are variables that predict the efficacy of ESI in patients with PHN. Patients and methods: We retrospectively identified patients seen at Mayo Clinic who had PHN and received ESI. From their medical records, we abstracted the demographic variables, concurrent medication use, anatomic approach and medication for ESI, and degree of pain relief at 2 and 12 weeks' postintervention. Results: None of the studied variables were significantly associated with efficacy of ESI in patients with PHN. PHN that began <11 months before treatment was predictive of a response to ESI at 12 weeks postintervention (positive predictive value, 55%). Patients who reported poor ESI efficacy 2 weeks after the intervention had a 94% chance of still having pain at 12 weeks. Conclusion: For this cohort of patients with PHN being treated with ESI, no demographic characteristics, concurrently used medications, or type of ESI were associated with ESI treatment efficacy at 2 or 12 weeks after the intervention.
Introduction local infiltration, sympathetic nerve blocks, and intrathecal injections. However, the reported efficacy of the invasive methods also is inconsistent. [13] [14] [15] [16] [17] Epidural steroid injection (ESI) with the transforaminal and interlaminar administration of steroids and local anesthetics is among the more common treatments for patients with refractory PHN. However, its effectiveness is controversial. To our knowledge, the only study investigating factors associated with improved efficacy of transforaminal ESI for PHN reported a symptom duration of <3 months as the only significant predictor of benefit. 18 The specific aims of the present study were to seek other factors associated with the efficacy of ESI in our patient population with PHN and to report our experience for therapeutic success with ESI.
Methods
The Mayo Clinic Institutional Review Board approved this retrospective study.
We searched electronic health records to identify patients with PHN managed by ESI who were seen at Mayo Clinic (Arizona, Florida, and Rochester campuses) from January 1, 1997, through April 1, 2018. PHN was defined as pain in the area of the eruption that persisted for >90 days after the onset of the rash. [19] [20] [21] [22] The following patient data were recorded: age, sex, comorbidities, concurrent medications, duration of PHN, anatomic approach of ESI, medication used for ESI, number of blocks, treatment date, and degree of pain relief at 2 and 12 weeks' postintervention. Pain relief was noted in the records in multiple ways: 1) as "good," "moderate," or "poor"; 2) as percent pain relief; or 3) as a point reduction on a pain scale (1-10, with 10 being severe pain). For records showing percent pain relief or pain scales, we considered up to 20% or a 2-point reduction as poor relief; 30-60% or a 3-to 6-point reduction as moderate relief; and >70% or at least a 7-point reduction as good relief. All patientspecific identifiers were removed from the data set before analysis. Univariate logistic regression using the Firth penalized likelihood approach 23 was used to investigate the association between patient characteristics, concurrent medication use, type of intervention, and moderate-to-good pain relief outcomes at 2 and 12 weeks' postintervention. Receiver operating characteristic analysis and the Youden index were used to establish the optimum cutoff point for PHN duration that would be predictive of moderate-to-good pain relief at 12 weeks. The statistical analysis was completed using SAS software, version 9.3 (SAS Institute Inc.,Cary, NC, USA).
Results
Our initial search of the electronic health records, using the terms "epidural steroid injection" and "postherpetic neuralgia," yielded 528 medical records. The records were reviewed, and we identified 42 patients meeting the definition of PHN from reactivation of HZ who were treated with ESI (54.8% male). Table 1 summarizes the demographic and clinical characteristics of the patients. We did not identify any significant association between moderate-to-good pain relief (at 2 or 12 weeks post-ESI) and patient demographics, concurrent medication use, ESI approach, or medications injected for the intervention (Tables 2 and 3 ). Patients who reported poor ESI efficacy 2 weeks after the intervention had a 94% chance of still having pain at 12 weeks. Of the 24 patients who had a moderate-to-good pain relief 2 weeks after ESI, 19 (79%) had persistent relief after 12 weeks. PHN duration <11 months was predictive of moderate-to-good pain relief at 12 weeks' post-ESI, with a positive predictive value of 55.2% (Table 4) .
Discussion
PHN is associated with an impaired quality of life, especially for elderly patients. 24 Current American Academy of Neurology guidelines 13 for reducing PHN-associated pain recommend TCA, anticonvulsants such as gabapentin and pregabalin, opioids, and topical lidocaine. However, at least 30% of patients with PHN have unsatisfactory relief of pain with these suggested treatments. 25 Hence, regional anesthetic procedures, including subcutaneous anesthetic and steroid injections, sympathetic and intrathecal nerve blocks, and ESI, are often used for management of PHN, even though these treatments are not strongly evidence based. Mixed results have been reported with subcutaneous anesthetic plus steroid injections or sympathetic nerve blocks in the management of PHN. 13, 14 Intrathecal injections have shown promise, but concerns regarding their safety remain. 11, 13, 14, [26] [27] [28] [29] [30] The risk of arachnoiditis reported with intrathecal injections likely will prevent this treatment from becoming widely used. 27, 28, 30 The role of ESI in established PHN is also controversial. Although ESI can induce short-term (1-month) pain relief for patients with acute HZ, it is not effective for preventing longterm PHN. 15 Two studies by Forrest 16, 17 compared the effects of ESI in patients with 1) PHN lasting >6 months or 2) posttraumatic neuralgia. He reported that the pain of PHN was significantly reduced by ESI with local anesthetics, but the treatment was not as effective for patients with posttraumatic neuralgia. However, it is unclear whether an interlaminar or transforaminal approach was applied.
A case report by Mehta et al 5 In our study, 97% of patients were treated with interlaminar ESI. We did not identify any factor that predicted an increased likelihood of moderate-to-good pain relief with interlaminar ESI at 2 and 12 weeks' postintervention. However, we verified the overall effectiveness of the intervention with ESI and noted a sustained benefit when the therapy was given to patients with PHN duration <11 months.
A limitation of our study was that we had only 1 patient for whom a transforaminal approach was confirmed. The transforaminal approach delivers therapy close to the site of inflammation of the targeted dorsal root ganglion and spinal nerve, thereby possibly providing the greatest potential for benefit with limited systemic impact. 33, 34 We are aware of no published studies that have compared the effect of interlaminar and transforaminal ESI for PHN. Our study was also limited by its retrospective design; therefore, some aspects of data collection may have been incomplete. A high number of our patients presented to their primary care physicians at the time of HZ, and data such as pain severity and antiviral and adjuvant treatment determined at those consultations were not available for review. Our sample size was small and the study may have been underpowered.
Inherent risks of ESI include infection, bleeding, and minor trauma along the course of the needle; such risks must be acknowledged when considering this treatment. 35 In conclusion, this study is the first to investigate predictive factors associated with the efficacy of interlaminar ESI in patients with PHN. PHN duration <11 months was predictive of moderate-to-good pain relief 12 weeks after ESI. Additionally, 80% of patients Abbreviations: ESI, epidural steroid injection; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. 
Abbreviation list
ESI, epidural steroid injection; HZ, herpes zoster; PHN, postherpetic neuralgia.
Disclosure
All authors report no conflicts of interest in this work. Note: a We sought to establish the optimum cutoff point for PHN duration that would be predictive of moderate-to-good pain relief at 12 weeks.
Abbreviations: NPV, negative predictive value; PHN, postherpetic neuralgia; PPV, positive predictive value.
